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COMBINATION OF SULPHASALAZINE AND METHOTREXATE 
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ARTHRITIS: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, 
52 WEEK CLINICAL TRIAL*
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Hospital Arnhem, The Netherlands
SU M M A R Y
To compare the efficacy and safety of sulphasalazine, methotrexate, and the combination of both in patients with early 
rheumatoid arthritis (RA), not treated with disease-modifying anti-rheumatic drugs previously, we conducted a double-blind, 
double-dummy, controlled, clinical trial. One hundred and five patients with active, early RA, rheumatoid factor and/or HLA 
DR 1/4 positive were randomized between sulphasalazine (SSZ) 2000 (maximum 3000) mg daily, or methotrexate (MTX) 7.5 
(maximum 15) mg weekly, or the combination (COMBI) of both, and were followed up by a single observer for 52 weeks. 
The mean change over time per patient, including all visits, in Disease Activity Score (DAS) was: SSZ: —1.6 (95% Cl -2 .0  to 
-1.2); MTX: -1 .7  (-2 .0  to -1.4); COMBI: -1 .9  (-2 .2  to -1.6); the difference week 0-week 52 (SSZ, MTX, COMBI respect­
ively): DAS: —1.8, -2 .0 , —2.3, Ritchie articular index: —9.2, —9.5, —10.6, swollen joints: —9.2, —12.4, -14.3, erythrocyte sedi­
mentation rate: —17, —21, —28. Nausea occurred significantly more in the COMBI group. The numbers of drop-outs due to 
toxicity were SSZ 9, MTX 2, COMBI 5, In conclusion, there were no significant differences in efficacy between combination 
and single therapy, only a modest trend favouring COMBI. The results of MTX and SSZ were very comparable. Nausea 
occurred more often in the COMBI group; the number of withdrawals due to adverse events did not differ significantly.
K e y  w o r d s :  Combination therapy, Sulphasalazine, Methotrexate, Early rheumatoid arthritis.
T h e  treatment o f  rheumatoid arthritis (RA) in its 
early phase relies on pharmacological means. Since 
RA is a disease which is often characterized by early 
occurring progressive and irreversible joint damage  
[1], and in the early phase the disease is probably the 
most responsive pharmacologically [2], drug treat­
ment should be instituted early. The results o f  current 
therapy in early RA  are not satisfactory due to lack 
o f  sufficient response. T o overcome this, com bina­
tions o f anti-rheumatic drugs have been proposed  
and used, analogous to anticancer treatment [3-6], 
The general impression is that while definite conclu­
sions cannot be drawn due to a lack o f  randomized  
controlled studies, there are some indications that 
combination therapy is more effective, but also more 
toxic. Which drugs to com bine and how to use these 
combinations, e.g. to start with multiple drugs and 
taper them off, or to start with one drug and, when a
response is lacking, add another, isStl
unclear.
The present study focuses on RA patients who had 
early and active disease, and who had not been 
treated with disease-m odifying anti-rheumatic drugs
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(D M A R D s)  before. Participants had to have indica­
tions o f  a worse prognosis (rheumatoid factor posit­
ive and/or certain PILA types) in order to prevent 
overtreatment. M ethotrexate (MTX) was chosen to 
be com bined with sulphasalazine (SSZ) because both 
are likely to be superior to some other D M A R D s  
with respect to efficacy and toxicity [7, 8]. Recently, 
we summarized the studies on this combination; the 
early impression was that the combination was effec­
tive, without a significant rise in toxicity, in patients 
who had already been treated with other second-line 
anti-rheumatic drugs [9].
In the present study, we tried to answer the ques­
tion whether the com bination o f MTX and SSZ is 
superior to M T X  or SSZ alone, and whether there is 
a difference between M T X  and SSZ in the initial 
treatment o f  early RA patients.
P A T I E N T S  A N D  M E T H O D S
P atient selection
Patients with R A  according to the A CR  criteria 
who were aged ^ 18  yi\ and with symptoms attribut­
able to RA with a duration o f  12 months maximum, 
were included. They were selected from all consecu­
tive patients w ho attended six peripheral and one 
academic clinic in a period o f  18 months. A positive 
rheumatoid factor and/or H L A -D R 4 and/or H.LA- 
DR1 positivity had to be present. The arthritis had 
to be active: the Disease Activity Score (D A S) being 
^3.0  (see below). Preceding drug treatment for RA
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other than analgesics and non-steroidal anti-inflam­
matory drugs (N SA ID s) was not allowed. Patients 
with contraindications to the use o f  SSZ or M TX  
were excluded. Informed consent had to be obtained.
Study design
This was a randomized, controlled, double-blind 
52 week trial with one observer. Patients were ran­
domized in blocks o f  six between SSZ plus MTX- 
placebo, M T X  plus SSZ-place bo and the combina­
tion of SSZ plus MTX, The study was approved by 
the ethical review board o f  each participating clinic.
Treatment
The patients were allocated to initial treatment 
with SSZ EC 500 mg twice daily increased to 
1000 mg twice daily in 10 days, +  MTX-matching  
placebo, 3 tablets/week; or M TX tablet 2.5 mg, 3 
tablets in a single dose/week, taken together +  SSZ- 
matching placebo in the same dose as above; or
M TX , the same dosages as above. All study 
tablets were prepacked in blister packages.
If a patient had the same or higher D A S (see 
below) and no prohibitive toxicity after 16 weeks of  
treatment with the study medication, the medication 
was changed as follows. The SSZ (or placebo) dose 
was increased to 6 tablets/day and the M T X  (or 
placebo) dose was increased to 6 tablets/week. Once 
started, the high dose was continued throughout the 
study. If the higher dose was not effective after 8 
weeks (as defined above), the patient was withdrawn. 
In the case o f  tolerable minor toxicity, the SSZ dose 
(or placebo) was lowered to 2 tablets/day and the 
M TX dose (or placebo) to 2 tablets/week. If a major 
severe adverse event (any event possibly related to 
the study medication causing hospitalization or 
death, or the possibility o f  such if the administration 
o f  the medication is continued) was suspected or 
occurred, the patient was immediately withdrawn,
All patients had a concom itant NSA1D in a dose 
which was preferably not altered during the study 
period. N o  systemically administered corticosteroids 
were permitted. When local corticosteroids had to be 
employed, the treated joint was omiLted from evalua­
tion from the time of injection onwards.
Evaluation
The patients were evaluated 2-weekly for the first 4 
weeks and 4-weekly thereafter until week 52, 14 visits 
in total. All clinical evaluations were made by one
observer (CJH).
The primary evaluation criterion was the mean 
change in the DAS over time for each individual 
patient. The DAS consists o f  the Ritchie articular 
index, the number o f  swollen joints and the erythro­
cyte sedimentation rate (ESR) [10], The mean change 
in DAS over Lime reflects all the changes relative to 
baseline and was calculated in the following way: the 
summation o f  0.5 x D A S week 2, 0.5 x DAS week 4 
(only 2-weelc intervals) and the DAS values o f  the 
next 12 visits (including week 52) divided by 13, 
minus the D A S of week 0 for each individual patient.
Secondary evaluation criteria were the number of  
patients with a good response according to the 
EULAR criteria [11], the mean change over the first
12 weeks (calculated in the same way as the primary 
efficacy variable, reflecting early changes) and week 0 
and week 52 concerning: the DAS score, the number 
of painful joints (53 joints), the Ritchie articular 
index [12], the number of swollen joints (maximum o f  
44 joints, not graded), pain expressed by the patient 
on a visual analogue scale (VAS) ranging from 0 to 
100 mm, general wellbeing expressed by the patient 
on a VAS of 0-100 mm, patient and physician global 
assessment of the actual disease activity (five-point 
ordinal scale) at each visit, the Health Assessment 
Questionnaire score and the degree o f improvement 
of disease activity at the final evaluation (on a five- 
point ordinal scale), grip strength (kPa), the number 
of patients with an increase in dose, the number o f  
joints having an intra-articular corticosteroid injec­
tion.
Compliance was checked by interviewing the 
patient and pill counting.
Laboratory evaluation, performed every 4 weeks, 
consisted of ESR, C-reactive protein (mg/'l), haemo­
globin content (mmol/1) and haematocrit, mean red 
cell volume (fl), WBC count with differential count, 
platelet count, alanine and aspartate aminotransfer­
ase (IE/ml), gamma glutamyl transferase (IE/ml), 
alkaline phosphatase (IE/ml) and creatinine in serum 
(¿¿mol/1).
Toxicity was monitored every visit by interviewing 
the patients, physical examination and laboratory in­
vestigations.
*( 1 /  i / >
I I* I I m s
All analyses were based on an intention to treat 
using end point analysis, i.e. the last observation car­
ried forward. The primary evaluation criterion was 
the mean change in the DAS (see above), reflecting 
the area under the curve of the DAS corrected for 
the DAS at baseline. The difference in the values o f  
this corrected area under the curve between the treat­
ment groups was tested by analysis of covariance
(ANCOVA).
Analysis o f  covariance was carried out to correct 
for differences in baseline values. Comparison of the 
three treatment groups at week 0 and 
between the week 0 and week 12 and week 52 values, 
and the mean changes over time o f  various variables, 
was made using ANCOVA, Kr uskal.1-Wallis or x2 
tests, as appropriate. Survival curves were analysed 
by the life table technique (log-rank test) using the 
frequencies together with the time to withdrawal.
A two-sided P value o f 0.05 was considered to be 
statistically significant.
R E SU L T S
A total of 105 patients were included in the study: 
34 in the SSZ group, 35 in the M TX group and 36 in 
the COMBI group. The baseline characteristics of the
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TABLE I
Baseline characteristics, means (s.d.) or numbers
Variable SSZ MTX COMBI
Number 34 35 36
Age (yr) 56.8 (13.0) 54,9 (13.2) 57.0 (12.2)
Female/im le 21/13 23/12 24112
Disease duration (mouths) 3.1 (1.9) 3.0 (2.3) 2.6 (1.4)
Rheumatoid factor positive/negative 33/1 33/2 34/2
HLA-DR1, present/absent 10/24 10/25 10/26
H LA-DR4* present/ubsent 18/16 18/17 18/18
DAS 4,6 (0.8) 4.7 (0.9) 5.0 (0.8)
No. of painful/tender joints 20.8 (8.6) 20.6 (8.1) 24.8 (9.5)
Ritchie articular index 15.1 (6.0) 13.4(6.4) 16.5 (6.3)
No. of swollen joints 17.0 (7.2) 19.9 (8.4) 20.8 (6.9)
ESR 50.7 (24,1) 50,3 (26.6) 55.3 (32.2)
HAQ score 0.97 (0.86) 0.92 (0.84) 1.20 (0.82)
Nodules present/absent 3/31 4/31 4/32
DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire
patients are given in Table I. A total of 20 patients 
withdrew prematurely (before week 52) from the 
trial. Three patients in the SSZ group and one patient 
in the COMBI group were withdrawn before the end 
of their follow-up because of inefficacy. For reasons 
of toxicity, nine patients in the SSZ group, two in the
MTX group and five in the COMBI group ended
i
their participation (see also Table IV). The time to 
withdrawal was shorter in the SSZ group, compared 
to the other two treatment groups; the difference was 
significant (P = 0.006).
The primary evaluation criterion, i.e. the mean 
change (95% confidence intervals) in DAS, by inten- 
tion-to-treat analysis, was —1.6 (—2.0, —1.2) in the 
SSZ group, —1.7 (—2.0, —1.4) in the MTX group and 
—1.9 (—2.2, —1.6) in the COMBI group. The differ­
ences were statistically not clinically significant. In 
Table II, the differences between the three groups are 
given using the adjusted means and these were tested 
by analysis of covariance to correct for the differ­
ences in baseline values. In Table III, the results 
(unadjusted numbers) of the primary and secondary 
evaluation criteria are given. The numbers of patients 
with a response according to the ACR criteria [13] at 
the end of study were 25 for SSZ, 25 for MTX and 
28 for the COMBI. According to the EULAR defini­
tion [11], the numbers o f patients with a good
response at the end of study were 14 for SSZ, 15 for 
MTX and 14 for the COMBI. The distribution in 
time of good responders (EULAR definition) is 
depicted in Fig. 2. The time to good response among 
the good responders tended to be shorter in the SSZ 
group: a mean of 16.8 weeks compared to 27.2 weeks 
for MTX and 22.4 weeks for COMBI. In a life table 
analysis* considering all patients, this difference was 
not statistically significant.
The numbers o f patients judging their disease as 
moderately/much improved at the final assessment 
were 12/11 in the SSZ-treated group, 12/19 for MTX 
and 13/21 for COMBI (P  =  0.0175). These numbers 
for the investigator’s final assessment were: SSZ: 
9/13; MTX: 15/16; COMBI: 9/22 (P = 0.06).
Compliance 
The percentage of tablets 
patients in all subgroups.
taken was >90% in all
Dose alterations
The dose of the medication was increased in 11 
patients in the SSZ group, in 11 in the MTX group 
and in seven in the COMBI group (NS).
Concomitant medication (excluding the NSAIDs) 
Twenty patients in the SSZ group, 15 in the MTX 
group and 28 of the COMBI patients had any con-
TABLE H
Di (Ve re aces!t; between the treatment groups, adjusted*}* means (95% Cl)
Variable COMBI vs SSZ* COMBI vi MTX* MTX w SSZ*
Mean changef in DAS over all 52 weeks 0.1 (-0.3, 0.5) 0.04 (-0.4, 0.5) 0.06 (—0.3, 0.5)
Mean change:): in DAS over the firsl 12 weeks -0.06 (—0.3, 0.2) 0.03 (—0.3, 0.3) -0.09 (-0.4, 0.2)
Change in DAS week 52 -  week 0 0.3 (-0.2, 0.8) 0.02 (-0.5, 0.6) 0.3 (-0.3, 0.8)
Change in RAI week 52 — week 0 0.6 (-1.7, 2.9) -0.85 (-3 .2 , 1.5) 1.4 (-0.9, 3.8)
Change in no. of swollen joints, 
week 52 -  week 0 1.8 (—0.9, 4.6) 1.1 (-1.5, 3.8) 0,7 (-2.0, 3.4)
Change in ESR, week 52 -  week 0 8>7 (-0.6, 18.1) 4.2 (—5,1, 13.5) 4.6 (-4.9, 14.0)
*A positive value means an advantage for the first mentioned group, no significant differences. 
i'Ana lysis of covariance, baseline values as co varia tes.
:j;The mean per patient of all changes from baseline to the individual lime points (week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52: 
the values of week 2 and week 4 were divided by two).
TABLE III
Change in efficacy variables, unadjusted means (95% Cl)
>
>
O
c/a
>
îïî
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on
Mean chanse over 52 weeks* Mean chanse over the first 12 weeks Chanse from baseline to week 52
Variable SSZ MTX COMBI SSZ MTX COMBI SSZ MTX COMBI
DAS -1.6 —1.7 -1.9 -1.1 -1.0 - L I -1.8 -2.0 -2.3
(-2.0. —1.2) (-2.0. -1.4) (-2 .2 ,-1 .6 ) (-1.3, -0.9) (-1.2, -0.8) (-1.3, —0.9) (—2.3. —1.3) (-2 .4 ,-1 .7 ) (-2.7. -1.9)
No. of swollen joints -7 .9 —10,2 -11.3 -4.8 -5.8 -6.1 -9 .2 -12.4 -14.3
(—10.1. —5.7) (-12.5. —8.0) (-13.5, -9.2) (-6.2. -3.5) (-7.3. —4.4) (-7.5. —4.7) (-12.2. -6.3) (-15.4, -9.5) (—17.3, -11.4)
Ritchie articular index -8.6 -8 .2 -9 .4 -7.1 —6.1 —6,8 -9 .2 -9.5 -10.6
(-10.7. -6.5) (-1 0 .L -6.4) (-11 .L -7.7) (—8.7. —5.6) (-7.7. -4.5) (—8.2, -5.4) (-11.7. —6.8)
« •
(-11.6, -7.5) (-12.5, -8.7)
No. of painful joints -11.7 -13.0 -14.S —9.0 -9.3 -10.0 -12.5 -15.2 -16.9
(-14.4. -9.0) (-15.4. -10.5) (-17.5, —12.0) (—10.9. -7.2) (-11.5. -7.1) (-12.0. -8.0) (-15.9. -9.1) (-18.2.-12.2) (-20.4, -13.5)
VAS general health (mm) -14.1 -15.1 -16.6 -8.6 -10.8 -9.3 -15.4 -21.3 -20.6
(-22.6. -5.5) 1-22.0. -8.2) (-22.4. -10.7) (—15.0, -2.1) (-15.9. -5.6) (-14.7. -3.9) (—25.8, —5.0) (-30.2. -12.3) (-27.6, -13.7)
VAS pain (mm) H n —— 1 -19.3 -20.9 -Î8 .I -12.3 -13.1 -25.2 -25.1 -25.1
(-33.4, -14.0) (-26.0 .-12.5) (-28.9. -12.9) (-25.2. -11.1) (-19.0. -5.6) (-20.3. -5.9) (-36.4. -14.0) (—32.8. -17.5) (-33.8. —16.5)
Grip strength fkPa) 14 13 15 8 6 7 16 16 21
(8. 20) (9, 16) (10,20) (4. 13)
*
(4. 9) (3. 10) (9, 24) (1L 22) (14. 28)
HAQ score -0.32 -0.46 -0.51
f—0.53. -0.10) (-0.68. -0.25) (-0.76. -0.26)
ESR (mm) -17 — 17 -23 -10 -10 -10 -17 -21 -28
(-24, -10) C—23, -11) ( -3 0 .-1 5 ) (-15. -5 ) (-15, -6 ) (-16, —4) (-26, -8 ) ( -2 8 .-1 5 ) (-37, -19)
MTX. methotrexate: COMBI, combination of methotrexate and sulphasalazine; SSZ. sulphasaiazine: DAS, Disease Activity Score (see the text): HAQ. Health Assessment Questionaire.
*The mean per patient of ail changes from baseline to the individual time points (week 2. 4, 8, 12, ! 6, 20, 24. 28, 32, 36, 40, 44.. 48 and 52; the values of week 2 and week 4 were divided by
two l.
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Disease Activity Score
12 16 20 24 28 32 36 40 44 48 52
Time (weeks)
■ SSZ  ♦ VITX *  COMBI
Fig. L— Mean Disease Activity Score, SSZ, sulphasalazine; MTX, 
methotrexate; COMBI, combination of both.
comitant medication. Folic  acid was given to correct 
deficiency in two patients in the SSZ group, one in 
the MTX group and three in the C O M BI group. 
Intra-articular injections o f  corticosteroids were spar­
ingly and evenly administered (four injections in SSZ, 
three in MTX, five in CO M BI),
Adverse events 
The number of patients experiencing some kind o f  
adverse event (Table IV) was not different am ong the 
treatments. All events were reversible on lowering the 
dose or stopping the medication. The adverse events 
possibly or probably related to the treatment 
occurred significantly m ore often in the C O M BI-  
treated patients. This was due to the significantly 
higher incidence o f mild nausea. One patient treated 
with SSZ withdrew due to anaemia. There were three 
patients with a serious adverse event according to the 
good clinical practice definition, ail occurring in the 
SSZ group. Two patients had dyspnoea, one prob-
% Good responders
50
40
30
20
10
** K
A
4
•  * .
/ /
/ ■ ' +
A* > i•» ...... *• •••.... . . , j .. . •  - . * ■ - *
0 4 8 12 16 20 24 28 32 36 40 44 48 52
Time (weeks)
■ SSZ ♦ MTX *  COMBI
Fici, 2 .—Percentage of good responders (EULAR definition). SSZ,
sulphasalitzine; MTX, methotrexate; COMBI, combination of 
both.
TABLE IV
Adverse events (AE), no. of patients (reason for premature with­
drawal)*
SSZ MTX COMBI
Total no. of patients 34 35 36
Any AE 30 27 32
Possible/probablet 16 11 23
Withdrawal due to AE 9 2 5
Dose reduction due to
AE >2  weeks 1 1 0
Nausea 10(1) 9(2) 23:J: (4)
Abdominal pain/
discomfort 9(1) 7 13
Stomatitis 1 2 i
Pyrosis 2 3 5
Increase in transaminases
>2 x normal 4(1) 5 2
Haeinntological K D 1 0
Flu/flu-like symptoms/
upper respiratory tract
infection 6 7 10
Central nervous system
dizziness 6 3 4
Headache 6 4 4
Neuropathy 1 0 1 (0
Dyspnoea 2 (2) 0 2
Rash 5(3) 2 0
"’'One patient can contribute more than once, 
t P «  0.023. 
tP  = 0.002,
ably due to heart failure and the other due to a 
chronic obstructive lung disease, although a drug- 
induced pneum onitis could not be ruled out with 
certainty. The third patient was hospitalized for 
resection o f  the metatarsal heads.
D I S C U S S I O N
In this double-blind, randomized, double-dummy 
controlled study of 105 early RA patients, we tried to 
answer the question whether the combination o f SSZ 
and M T X  is more effective than the single com pon­
ents, w ithout a disproportional increase in toxicity, 
and whether there was a difference between SSZ and 
M T X . A lth ou gh  there was a slight trend that the 
com bination was somewhat more potent than the in­
dividual com ponents, the general conclusion is that 
the efficacy and toxicity are comparable in the three 
treatment groups. The differences between the 
combination therapy and the single components  
(Table II), a lthough almost invariably in favour of  
the com bination, were unimpressive and the relatively 
small confidence intervals [14] make important differ­
ences less likely. Importantly, being the first double- 
blind direct comparison between SSZ and M TX, we 
did not observe any relevant differences in the mean 
change over time o f  the D A S  between the two groups 
in the doses used. Interestingly, the time to good  
response tended to be shorter in the SSZ-treated 
patients compared to the M T X  patients.
Given the current tendency to use higher doses o f  
M T X , one could speculate on the implications for 
the results o f  the present study. Possibly, a difference
HAAGSMA ET AL.: SULPHASALAZINE A ND  METHOTREXATE IN EARLY RA 1087
1*1 v . • * • • r •••• •*
would arise in favour o f  M T X  over SSZ. The n o n ­
significant differences between the C O M B I and M T X  
now present could disappear altogether with an 
increasing contribution o f  M T X  to the efficacy o f  the 
combination.
The toxicity was not very different, notw ithstand­
ing the statistically significant greater incidence o f  
mild nausea in the C O M BI group. This is reflected in 
the number o f  withdrawals, which did not differ sig­
nificantly, although there was a tendency for a higher 
drop-out rate for the SSZ-treated patients, mainly 
due to skin rashes. Whether the higher number o f  
concomitant drugs in the C O M B I group could also  
explain the greater toxicity remains speculative.
The place o f  this and other com binations o f  sec­
ond-line anti-rheumatic drugs in the therapy o f  R A  is 
still uncertain; theoretically, one can adopt various 
strategies o f  com bining [9], roughly divided into two  
variants: to start com binations from the beginning  
and taper them off when positive results are obtained  
(‘step-down-bridge’ approach [15]), and to add a 
second anti-rheumatic drug once the first one is not 
successful (‘adding-on’ or "step-up’ strategy). When  
judging the results o f  the various studies concerning  
the combination o f  SSZ and M T X , a picture emerges 
of increased efficacy w ithout additional toxicity when  
the 'step-up’ strategy is em ployed [9]. The only ran­
domized trial on the com bination o f  M T X  and SSZ  
was carried out in patients with m ore advanced RA  
[16]. Although it had an open design and som e expec­
tation bias cannot be excluded with certainty, a clear 
benefit was observed for the com bination over M T X  
alone, in patients w ho had insufficient efficacy o f  SSZ  
alone. The majority o f  those patients initially had a 
favourable response to SSZ, preceding the start o f  
the trial. The reaction to M T X  alone (with a rela­
tively low dose) was m odest in that study. So differ­
ences between the results o f  that study and the 
present one might be explained by: another patient 
population; early vs more advanced RA; M T X  help­
ing to overcom e secondary resistance to SSZ. The  
mechanism o f  this is unclear, but folate metabolism  
is possibly involved [17, 18], A nother explanation for 
the discrepancy between the results o f  the two studies 
might be a ceiling effect in the present study: given 
the large number o f  patients with a good response, 
there is only a limited possibility for further im prove­
ment, thus compressing the differences.
Another very recently published study on the c o m ­
bination o f  SSZ, M T X  and also hydroxychloroquine  
as a triple therapy in patients who failed on at least 
one D M A R D , reported an increased efficacy o f  the 
triple therapy over the com bination  o f  SSZ and 
hydroxychloroquine and over M T X  alone, without  
an increase in toxicity [19]. The results o f  SSZ in half  
the usual dose combined with a full dose o f  hydroxy­
chloroquine were equal to M T X  in a dose up to
17.5 mg. Controls using M T X  with either SSZ or 
hydroxychloroquine were lacking, it was surprising 
that ±79%  o f  the M T X  patients had a good  response  
after 9 m onths o f  treatment and no toxicity that
caused withdrawal, and subsequently ~60%  o f  these 
patients dropped out because o f  treatment failure 
and/or toxicity, within 12 months. This seems con­
trary to other experience with M TX , where, once a 
good response is achieved, this is maintained for a 
longer time [20].
The results o f  the present study, applying the fcstep- 
down-bridge’ or ‘parallel’ strategy in early RA, do 
not support the preliminary success o f  the com bina­
tion o f  SSZ and M T X  using the \step-up’ strategy [9], 
Whether this is a result o f  the chosen strategy: the 
‘step-up’ approach is more effective than the 'step- 
d ow n ’, or depends on the specific anti-rheumatic 
drugs, will be clearer when other combinations o f  
anti-rheumatic drugs are tested in the same category 
o f  patients.
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